Tamanho do Mercado Europeu de Terapia Fotodinâmica do Câncer, Tendências, Relatório de Crescimento 2032.

Europe Cancer Photodynamic Therapy Market

Tamanho do mercado em biliões de dólares

CAGR : 5.80 %

USD 872.14 Million USD 1,353.25 Million 2024 2032

Período de previsão	2025 –2032
Tamanho do mercado (ano base )	USD 872.14 Million
Tamanho do mercado ( Ano de previsão)	USD 1,353.25 Million
CAGR	5.80 %
Principais participantes do mercado	Novartis Pharma AG Galderma SA Bausch Health Companies Inc. Photocure ASA ADVANZ PHARMA Corp.

Segmentação do Mercado Europeu de Terapia Fotodinâmica para o Câncer, por Tipo de Produto (Medicamentos Fotossensibilizadores, Dispositivos de Terapia Fotodinâmica), por Indicação de Câncer (Oncologia Cutânea, Cabeça e Pescoço, Esôfago, Pulmão, Bexiga, Colo do Útero, Próstata), por Modalidade de Terapia (Terapia Isolada, Terapia Adjuvante, Terapia Paliativa, Outras), por Técnica de Procedimento (Feixe Externo, Administração Intracavitária (Endoscópica), Administração Intersticial (Interna), Outras), por Estágio da Doença (Câncer em Estágio Inicial, Câncer em Estágio Avançado), por Perfil Demográfico do Paciente (Idosos, Adultos, Crianças), por Usuário Final (Hospitais, Clínicas de Dermatologia e Câncer de Pele, Centros Cirúrgicos Ambulatoriais (CCAs), Institutos Acadêmicos e de Pesquisa, Outros), por Canal de Distribuição (Licitações Diretas, Distribuidores Terceirizados, Online, Outros) - Tendências e Previsões do Setor até 2032

Tamanho do mercado europeu de terapia fotodinâmica para o câncer

O mercado europeu de terapia fotodinâmica para o câncer foi avaliado em US$ 872,14 milhões em 2024 e espera-se que atinja US$ 1.353,25 milhões até 2032, com uma taxa de crescimento anual composta (CAGR) de 5,8% durante o período de previsão.
O mercado é impulsionado principalmente pela crescente prevalência do câncer, pelo aumento dos gastos com saúde e pela maior conscientização sobre opções de tratamento avançadas. Melhorias rápidas na infraestrutura de saúde e a expansão de centros especializados em tratamento de câncer também contribuem para esse cenário.
Esse crescimento é impulsionado por fatores como iniciativas governamentais que promovem o diagnóstico precoce e terapias inovadoras, o grande número de pacientes e o aumento dos investimentos de empresas internacionais e locais em tecnologias de terapia fotodinâmica.

Análise do mercado europeu de terapia fotodinâmica para o câncer

O mercado de terapia fotodinâmica (PDT) para o câncer está experimentando um crescimento constante, impulsionado pelo aumento da prevalência do câncer, pela crescente conscientização sobre tratamentos não invasivos e pelos avanços em medicamentos fotossensibilizadores e tecnologias a laser.
Os mercados emergentes estão testemunhando uma rápida adoção da PDT, impulsionada por iniciativas governamentais, aumento dos gastos com saúde e crescimento da população idosa. No entanto, os altos custos do tratamento e o reembolso limitado continuam sendo os principais obstáculos, enquanto as inovações contínuas em terapias combinadas e fotossensibilizadores direcionados apresentam oportunidades significativas de crescimento.
A Alemanha deverá dominar o mercado europeu de terapia fotodinâmica para o câncer, com a maior participação de mercado, de 19,26% em 2025, impulsionada por uma infraestrutura de saúde avançada, alta adoção de tratamentos inovadores, fortes investimentos em pesquisa e desenvolvimento, políticas de reembolso favoráveis e conscientização sobre terapias minimamente invasivas.
A Alemanha deverá ser a região de crescimento mais rápido no mercado europeu de terapia fotodinâmica para o câncer durante o período de previsão, com uma taxa de crescimento anual composta (CAGR) de 8,9%, impulsionada pelo aumento da prevalência de câncer, pela expansão da infraestrutura de saúde, pela crescente conscientização sobre terapias avançadas e por iniciativas governamentais que promovem o diagnóstico precoce. Além disso, a crescente adoção de tecnologias inovadoras e o aumento da renda disponível impulsionam a demanda por terapia fotodinâmica na região.
O segmento de medicamentos fotossensibilizadores deverá dominar o mercado europeu de terapia fotodinâmica para o câncer, com uma participação de mercado de 75,15% em 2025, impulsionado por seu papel central no tratamento, alta especificidade no direcionamento às células cancerígenas, crescente aprovação de novos medicamentos, adoção cada vez maior em terapias combinadas e pesquisa e desenvolvimento contínuos que visam maior eficácia e redução dos efeitos colaterais.

Escopo do relatório e segmentação do mercado europeu de terapia fotodinâmica para o câncer.

Atributos	Análises Essenciais do Mercado da Seda
Segmentos abrangidos	Por tipo de produto: Medicamentos fotossensibilizantes, Dispositivos para terapia fotodinâmica Por indicação de câncer: Oncologia cutânea, Cabeça e pescoço, Esôfago, Pulmão, Bexiga, Colo do útero, Próstata Por modalidade terapêutica: Terapia isolada, Terapia adjuvante, Terapia paliativa, Outras Por técnica de procedimento: feixe externo, administração intracavitária (endoscópica), administração intersticial (interna), outras. Por estágio da doença: câncer em estágio inicial, câncer em estágio avançado Por perfil demográfico do paciente: Geriátrico, Adulto, Pediátrico Por usuário final: Hospitais, clínicas de dermatologia e câncer de pele, centros cirúrgicos ambulatoriais (ASCS), institutos acadêmicos e de pesquisa, outros. Por canal de distribuição: Licitações diretas, Distribuidores terceirizados, Online, Outros
Países abrangidos	Europa Alemanha Reino Unido França Itália Espanha Rússia Peru Suíça Bélgica Holanda Suécia Dinamarca Noruega Finlândia Resto da Europa
Principais participantes do mercado	Novartis Pharma AG (Suíça) Galderma SA (Suíça) Bausch Health Companies Inc. (Canadá) Fotocura ASA (Noruega) ADVANZ PHARMA Corp. (Reino Unido) Sun Pharmaceutical Industries Ltd. (Índia) Biofrontera AG (Alemanha) LUMIBIRD SA (França) LUZITIN SA (Portugal) Lumeda Inc. (Suécia) ImPact Biotech (Israel) biolitec Holding GmbH & Co KG (Alemanha) Modulight Corporation (Finlândia) THERALASE TECHNOLOGIES INC.
Oportunidades de mercado	Integração com outras terapias contra o câncer Desenvolvimento de novos fotossensibilizadores
Conjuntos de informações de dados de valor agregado	Além das informações sobre cenários de mercado, como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e principais participantes, os relatórios de mercado elaborados pela Data Bridge Market Research também incluem análise de importação e exportação, visão geral da capacidade de produção, análise de produção e consumo, análise de tendências de preços, cenário de mudanças climáticas, análise da cadeia de suprimentos, análise da cadeia de valor, visão geral de matérias-primas/insumos, critérios de seleção de fornecedores, análise PESTLE, análise de Porter e estrutura regulatória.

Tendências do mercado europeu de terapia fotodinâmica para o câncer

“Integração com outras terapias oncológicas”

A capacidade da terapia fotodinâmica (PDT) de produzir destruição localizada de células tumorais, ao mesmo tempo que estimula respostas imunes, a torna uma parceira atraente para o tratamento multimodal do câncer.
Cada vez mais evidências mostram que a PDT pode aumentar a liberação de antígenos tumorais, modular o microambiente tumoral e aumentar a infiltração ou ativação de células imunes — mecanismos que podem apresentar sinergia com inibidores de checkpoint imunológico, vacinas terapêuticas contra o câncer, quimioterapia ou radioterapia.
A combinação da PDT com terapias sistêmicas pode converter o controle local em respostas sistêmicas duradouras, permitir a redução da dose de agentes tóxicos e expandir as indicações (por exemplo, doença irressecável ou metastática).
Com a multiplicação da pesquisa clínica e translacional, a integração com outras modalidades representa um caminho valioso para ampliar a relevância clínica e a adoção comercial da PDT.

Dinâmica do mercado europeu de terapia fotodinâmica para o câncer

Motorista

“Prevalência crescente do câncer”

O aumento da prevalência do câncer em todo o mundo é um dos principais fatores que impulsionam a demanda por terapias como a terapia fotodinâmica (PDT).
Com o crescimento e envelhecimento da população, e com a melhoria das ferramentas de diagnóstico, o número de casos de câncer detectados a cada ano aumenta.
Taxas mais elevadas de fatores de risco, como tabagismo, obesidade, sedentarismo, poluição do ar e infecções em países de baixa e média renda, também contribuem para o aumento da incidência.
Com o aumento do número de pacientes que necessitam de modalidades de tratamento localizadas, eficazes, menos invasivas e com melhor custo-benefício, a PDT torna-se cada vez mais atrativa.
O crescente número de casos de câncer sobrecarrega os sistemas de saúde, criando uma pressão urgente por terapias que possam melhorar os resultados, reduzir os efeitos colaterais e ser implementadas de forma mais ampla.

Restrição/Desafio

“Profundidade limitada de penetração da luz”

Uma limitação significativa que dificulta a adoção e a eficácia mais amplas da terapia fotodinâmica é a penetração restrita da luz ativadora nos tecidos humanos.
Como os fotossensibilizadores precisam ser ativados por luz de comprimentos de onda específicos, a absorção e dispersão da luz pelo tecido reduzem a profundidade que a iluminação pode atingir.
Os fotossensibilizadores de luz visível geralmente funcionam apenas para tumores superficiais ou de fácil acesso; tumores mais profundos ou maiores continuam sendo um desafio.
Essa limitação leva à destruição incompleta do tumor, exige o uso de métodos invasivos de iluminação (por exemplo, sondas de fibra óptica, endoscopia), aumenta a complexidade do procedimento e pode resultar em desfechos insatisfatórios ou recidiva.
Até que avanços superem essa limitação, a Terapia Fotodinâmica (PDT) permanece restrita ao leque de tipos de câncer que pode tratar de forma não invasiva e eficaz.

Escopo do mercado europeu de terapia fotodinâmica para o câncer

O mercado é segmentado com base no tipo de produto, indicação de câncer, modalidade de terapia, técnica de procedimento, estágio da doença, dados demográficos do paciente, usuário final e canal de distribuição.

Por tipo de produto

Com base no tipo de produto, o mercado europeu de terapia fotodinâmica para o câncer é segmentado em medicamentos fotossensibilizadores e dispositivos de terapia fotodinâmica. Em 2025, espera-se que os medicamentos fotossensibilizadores dominem o mercado com uma participação de 75,15%, devido ao seu papel crucial na eficácia do tratamento, ampla aplicabilidade em diversos tipos de câncer e formulações versáteis (intravenosa, tópica, oral, intravesical e intraperitoneal). Os principais fatores que impulsionam essa dominância incluem a crescente prevalência de câncer, a adoção cada vez maior de terapias minimamente invasivas, as inovações contínuas em medicamentos e as aprovações regulatórias, que, em conjunto, fazem dos fotossensibilizadores os principais contribuintes para a receita, superando os dispositivos de terapia fotodinâmica.

O segmento de medicamentos fotossensibilizantes é o que apresenta o crescimento mais rápido no mercado europeu de terapia fotodinâmica (PDT) para o câncer, com uma taxa de crescimento anual composta (CAGR) de 5,9%, devido à crescente adoção de tratamentos oncológicos direcionados e minimamente invasivos. A crescente conscientização sobre a eficácia da PDT, os menores efeitos colaterais em comparação com as terapias convencionais e o desenvolvimento de fotossensibilizadores de última geração com seletividade tumoral aprimorada e maior penetração nos tecidos impulsionam a demanda. Além disso, pesquisas clínicas promissoras e aprovações de novos agentes fotossensibilizantes também contribuem para a expansão do mercado.

Por indicação de câncer

Com base na indicação do câncer, o mercado europeu de terapia fotodinâmica (PDT) para o câncer é segmentado em Oncologia Cutânea, Cabeça e Pescoço, Esôfago, Pulmão, Bexiga, Colo do Útero e Próstata. Em 2025, espera-se que o segmento de Oncologia Cutânea domine o mercado com uma participação de 52,21%, devido à alta prevalência de cânceres de pele, à ampla conscientização sobre a detecção precoce e à eficácia da PDT na obtenção de resultados estéticos superiores. O segmento se beneficia da ampla adoção de medicamentos fotossensibilizadores e dispositivos de PDT, especialmente para pacientes geriátricos e adultos, que representam a maior parcela da população. Além disso, a crescente demanda por terapias minimamente invasivas e direcionadas para queratoses actínicas, carcinoma basocelular e carcinoma espinocelular, juntamente com políticas de reembolso favoráveis em regiões-chave, reforça ainda mais sua liderança de mercado em relação a outras indicações de câncer.

O segmento de Oncologia Dermatológica é o que apresenta o crescimento mais rápido, com uma taxa de crescimento anual composta (CAGR) de 6,3% no mercado europeu de terapia fotodinâmica para o câncer, devido à crescente prevalência de câncer de pele, à maior conscientização sobre o diagnóstico precoce e à preferência por tratamentos minimamente invasivos com menos efeitos colaterais. A terapia fotodinâmica oferece ação direcionada, recuperação rápida e melhores resultados estéticos, tornando-a altamente favorável para a oncologia dermatológica. Além disso, os avanços tecnológicos em fotossensibilizadores e sistemas de emissão de luz estão impulsionando a adoção nesse segmento.

Por Modalidade de Terapia

Com base na modalidade terapêutica, o mercado europeu de terapia fotodinâmica (PDT) para o câncer é segmentado em terapia isolada, terapia adjuvante, terapia paliativa e outras. Em 2025, espera-se que o segmento de terapia isolada domine o mercado com uma participação de 41,20%, devido à sua eficácia como tratamento primário para cânceres localizados, incluindo câncer de pele, esôfago e pulmão. Os principais fatores que impulsionam essa dominância incluem alta eficácia, mínima invasividade, resultados estéticos superiores e crescente preferência clínica por terapias direcionadas. Regionalmente, a América do Norte e a Europa lideram a adoção da PDT isolada devido à infraestrutura de saúde avançada, estruturas de reembolso estabelecidas e alta conscientização dos pacientes, enquanto os mercados emergentes na Ásia-Pacífico estão testemunhando uma crescente adoção impulsionada pela crescente prevalência de câncer, expansão das redes hospitalares e maior acesso a tratamentos oncológicos modernos. Essas dinâmicas regionais, combinadas com o aumento da educação e da conscientização sobre os benefícios da PDT, reforçam a dominância da terapia isolada globalmente.

A terapia isolada é o segmento de crescimento mais rápido, com uma taxa de crescimento anual composta (CAGR) de 6,2% no mercado europeu de terapia fotodinâmica para o câncer, devido à sua simplicidade, custo-benefício e redução dos efeitos colaterais em comparação com as terapias combinadas. Ela permite o tratamento direcionado do tumor sem a necessidade de medicamentos ou intervenções adicionais, melhorando a adesão do paciente. A crescente adoção em ambientes ambulatoriais, a maior conscientização sobre tratamentos minimamente invasivos e os avanços em fotossensibilizadores e sistemas de distribuição de luz estão impulsionando ainda mais o rápido crescimento desse segmento.

Por meio da técnica de procedimento

Com base na técnica de procedimento, o mercado europeu de terapia fotodinâmica para o câncer é segmentado em feixe externo, administração intracavitária (endoscópica), administração intersticial (interna) e outras. Em 2025, espera-se que o segmento de feixe externo domine o mercado com uma participação de 68,97%, devido à sua natureza não invasiva, facilidade de uso e eficácia para tumores superficiais. A forte adoção na América do Norte e na Europa, apoiada por infraestrutura de saúde avançada e políticas de reembolso, juntamente com a crescente demanda na região Ásia-Pacífico devido à crescente prevalência e conscientização sobre o câncer, impulsiona sua liderança de mercado.

O segmento de administração intracavitária (endoscópica) é o que apresenta o crescimento mais rápido, com uma taxa de crescimento anual composta (CAGR) de 6,3% no mercado europeu de terapia fotodinâmica para o câncer, pois permite a administração minimamente invasiva e direcionada de luz e fotossensibilizador a tumores em órgãos ocos, reduz a exposição sistêmica e os efeitos colaterais, possibilita tratamentos repetíveis, melhora o acesso ao tumor em casos de câncer de esôfago, brônquios e bexiga e reduz o tempo de recuperação.

Por estágio da doença

Com base no estágio da doença, o mercado europeu de terapia fotodinâmica (PDT) para câncer é segmentado em câncer em estágio inicial e câncer em estágio avançado. Em 2025, espera-se que o segmento de câncer em estágio inicial domine o mercado com uma participação de 81,51%, devido à eficácia da PDT em atingir tumores localizados, minimizar danos ao tecido saudável e oferecer melhores resultados estéticos. O segmento se beneficia da alta conscientização dos pacientes, da preferência por tratamentos minimamente invasivos e da ampla adoção na América do Norte e na Europa, enquanto o aumento das taxas de diagnóstico de câncer e a expansão da infraestrutura oncológica na região Ásia-Pacífico reforçam ainda mais sua liderança de mercado.

O câncer em estágio inicial é o segmento de crescimento mais rápido, com uma taxa de crescimento anual composta (CAGR) de 5,8% no mercado europeu de terapia fotodinâmica (PDT), devido à crescente adoção de tratamentos minimamente invasivos, à maior conscientização sobre a detecção precoce e aos melhores resultados para os pacientes com a PDT. Os cânceres em estágio inicial respondem melhor às terapias direcionadas, resultando em maior eficácia e menos efeitos colaterais. Além disso, iniciativas governamentais de apoio e avanços em fotossensibilizadores e sistemas de distribuição de luz estão impulsionando uma penetração de mercado mais rápida nesse segmento.

Por dados demográficos do paciente

Com base nos dados demográficos dos pacientes, o mercado europeu de terapia fotodinâmica para o câncer é segmentado em geriátrico, adulto e pediátrico. Em 2025, espera-se que o segmento geriátrico domine o mercado com uma participação de 67,12%, devido à maior prevalência de câncer entre os idosos, à maior suscetibilidade a cânceres de pele e cutâneos e à preferência por tratamentos minimamente invasivos e direcionados. A forte adoção na América do Norte e na Europa é impulsionada por uma infraestrutura de saúde avançada e pela conscientização da população, além do crescimento da população idosa.

O segmento geriátrico é o que apresenta o crescimento mais rápido, com uma taxa de crescimento anual composta (CAGR) de 6,0% no mercado europeu de terapia fotodinâmica (PDT), devido à maior prevalência de câncer entre os idosos. O envelhecimento enfraquece o sistema imunológico e aumenta a suscetibilidade a vários tipos de câncer, impulsionando a demanda por tratamentos eficazes e minimamente invasivos, como a PDT. Além disso, a PDT oferece menos efeitos colaterais e recuperação mais rápida, tornando-a adequada para pacientes idosos que podem não tolerar terapias agressivas, o que impulsiona o crescimento do mercado nessa faixa etária.

Por usuário final

Com base no usuário final, o mercado europeu de terapia fotodinâmica (PDT) para o câncer é segmentado em hospitais, clínicas de dermatologia e câncer de pele, centros cirúrgicos ambulatoriais (CCAs), instituições acadêmicas e de pesquisa e outros. Em 2025, espera-se que o segmento de hospitais domine o mercado com uma participação de 41,33%, devido à sua infraestrutura abrangente, disponibilidade de departamentos de oncologia especializados e capacidade de oferecer tratamentos integrados de PDT. Hospitais públicos e privados, principalmente os de nível 1 e 2 na América do Norte e na Europa, lideram a adoção da terapia devido aos seus sistemas de saúde avançados e ao suporte de reembolso. A expansão das redes hospitalares e dos serviços de oncologia na região Ásia-Pacífico reforça ainda mais a dominância dos hospitais como os principais usuários finais da PDT para o câncer em todo o mundo.

O segmento de hospitais apresenta o crescimento mais rápido, com uma taxa de crescimento anual composta (CAGR) de 6,5% no mercado europeu de terapia fotodinâmica (PDT) para o câncer, devido à crescente adoção de tratamentos oncológicos avançados, ao maior fluxo de pacientes e à disponibilidade de departamentos de oncologia especializados. Os hospitais oferecem serviços abrangentes de PDT, incluindo diagnóstico, tratamento e cuidados pós-terapia, o que os torna preferíveis a clínicas independentes. Além disso, a crescente conscientização, as iniciativas governamentais e a cobertura de planos de saúde impulsionam ainda mais a adoção da PDT em hospitais.

Por canal de distribuição

Com base no canal de distribuição, o mercado europeu de terapia fotodinâmica para o câncer é segmentado em licitação direta, distribuidores terceirizados, online e outros. Em 2025, espera-se que o segmento de licitação direta domine o mercado com uma participação de 50,79%, devido à aquisição em grande escala por hospitais, programas governamentais de saúde e grandes centros de oncologia, o que garante custo-benefício e fornecimento confiável de fotossensibilizadores e equipamentos de PDT. A forte adoção na América do Norte e na Europa é impulsionada por sistemas estruturados de aquisição hospitalar e licitações de saúde pública, juntamente com a crescente demanda institucional.

O segmento de Licitação Direta é o que apresenta o crescimento mais rápido, com uma taxa de crescimento anual composta (CAGR) de 6,0% no mercado europeu de Terapia Fotodinâmica (PDT) para o câncer, devido ao aumento das aquisições de equipamentos avançados de PDT por governos e hospitais por meio de contratos diretos. Essa abordagem garante custo-benefício, aquisição mais rápida e fornecimento confiável para programas de tratamento de câncer em larga escala. Além disso, o aumento dos gastos públicos com saúde, as iniciativas governamentais para o tratamento do câncer e a preferência por compras centralizadas impulsionam a adoção da licitação direta em detrimento de distribuidores ou canais online.

Análise Regional do Mercado Europeu de Terapia Fotodinâmica para o Câncer

A Alemanha deverá dominar o mercado europeu de terapia fotodinâmica para o câncer, com a maior participação de mercado, de 19,26% em 2025, impulsionada por uma infraestrutura de saúde avançada, alta adoção de tratamentos inovadores, fortes investimentos em pesquisa e desenvolvimento, políticas de reembolso favoráveis e conscientização sobre terapias minimamente invasivas.
A Alemanha deverá ser a região de crescimento mais rápido no mercado europeu de terapia fotodinâmica para o câncer durante o período de previsão, com uma taxa de crescimento anual composta (CAGR) de 8,9%, impulsionada pelo aumento da prevalência de câncer, pela expansão da infraestrutura de saúde, pela crescente conscientização sobre terapias avançadas e por iniciativas governamentais que promovem o diagnóstico precoce. Além disso, a crescente adoção de tecnologias inovadoras e o aumento da renda disponível impulsionam a demanda por terapia fotodinâmica na região.
Além disso, a presença de importantes players de mercado e estruturas regulatórias favoráveis aceleram o crescimento do mercado e as taxas de adoção na região.

Análise do mercado de terapia fotodinâmica para câncer no Reino Unido e na Europa

O mercado de terapia fotodinâmica (PDT) para o câncer no Reino Unido e na Europa desempenha um papel significativo na indústria europeia de plásticos médicos, impulsionado por sua sólida infraestrutura de saúde, capacidades avançadas de pesquisa e centros de oncologia consolidados. A alta adoção de terapias inovadoras, o forte apoio governamental ao tratamento do câncer e os ensaios clínicos ativos impulsionam o crescimento do mercado. Além disso, as colaborações entre empresas farmacêuticas e instituições de pesquisa no Reino Unido aceleram o desenvolvimento e a comercialização da PDT, tornando-o um importante contribuinte para o mercado europeu.

Análise do mercado de terapia fotodinâmica para o câncer na Alemanha e na Europa

O mercado de terapia fotodinâmica (PDT) para o câncer na Alemanha e na Europa deverá crescer de forma constante, impulsionado por uma infraestrutura de saúde avançada, alta adoção de tratamentos inovadores contra o câncer e forte apoio governamental à pesquisa oncológica. A crescente conscientização sobre terapias minimamente invasivas, a incidência cada vez maior de cânceres como o de pele e o de pulmão, e as políticas de reembolso para novas terapias também contribuem para esse crescimento. Além disso, a presença de importantes fabricantes de dispositivos de PDT e as colaborações em pesquisa aceleram a penetração no mercado e o crescimento sustentado.

Os principais líderes de mercado que atuam no setor são:

Novartis Pharma AG (Suíça)
Galderma SA (Suíça)
Bausch Health Companies Inc. (Canadá)
Fotocura ASA (Noruega)
ADVANZ PHARMA Corp. (Reino Unido)
Sun Pharmaceutical Industries Ltd. (Índia)
Biofrontera AG (Alemanha)
LUMIBIRD SA (França)
LUZITIN SA (Portugal)
Lumeda Inc. (Suécia)
ImPact Biotech (Israel)
biolitec Holding GmbH & Co KG (Alemanha)
Modulight Corporation (Finlândia)
THERALASE TECHNOLOGIES INC.

Últimos desenvolvimentos no mercado europeu de terapia fotodinâmica para o câncer

Em fevereiro de 2023, a colaboração entre a Galderma e a German Medical Engineering (GME) representa um desenvolvimento estratégico no mercado de dermatologia e terapia fotodinâmica (PDT). Ao combinar o Metvix da Galderma, um fotossensibilizador líder para lesões pré-cancerosas e cânceres de pele não melanoma, com o dispositivo MultiLite da GME, a parceria fortalece a oferta de tratamentos integrados da Galderma e expande sua capacidade de fornecer tanto a PDT convencional com luz vermelha (C-PDT) quanto a PDT com luz artificial diurna (ADL-PDT), mais confortável para o paciente.
Em 2025, a McKesson concluiu a aquisição da Core Ventures (Community Oncology Revitalization Enterprise Ventures), adquirindo uma participação majoritária de aproximadamente 70% por cerca de US$ 2,49 bilhões, para fortalecer seu atendimento oncológico comunitário por meio do Florida Cancer Specialists & Research Institute.
Em 2025, a Biofrontera AG transferiu todos os ativos nos EUA relacionados ao Ameluz e ao RhodoLED para a Biofrontera Inc., recebendo uma participação acionária de 10% e royalties de 12 a 15% sobre as vendas do Ameluz nos EUA.

SKU-74823

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Click on image to enlarge

Painel interativo de análise de dados
Painel de análise da empresa para oportunidades de elevado potencial de crescimento
Acesso de analista de pesquisa para personalização e customização. consultas
Análise da concorrência com painel interativo
Últimas notícias, atualizações e atualizações Análise de tendências
Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência

Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE CANCER PHOTODYNAMIC THERAPY MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 PRODUCTION CONSUMPTION ANALYSIS

4.3.1 INTRODUCTION

4.3.2 PRODUCTION SIDE ANALYSIS

4.3.2.1 PHOTOSENSITIZER MANUFACTURING

4.3.2.2 DEVICE MANUFACTURING

4.3.2.3 RESEARCH AND INNOVATION

4.3.3 CONSUMPTION SIDE ANALYSIS

4.3.3.1 CLINICAL APPLICATION

4.3.3.2 TREATMENT VOLUMES AND TRENDS

4.3.3.3 DOSAGE AND PROTOCOLS

4.3.4 PRODUCTION–CONSUMPTION DYNAMICS

4.3.4.1 SUPPLY CONSTRAINTS

4.3.4.2 REGIONAL OVERVIEW

4.3.4.3 FUTURE OUTLOOK

4.3.5 CONCLUSION

4.4 COST ANALYSIS BREAKDOWN

4.4.1 INTRODUCTION

4.4.2 DIRECT MEDICAL COSTS

4.4.2.1 COST OF PHOTOSENSITIZERS

4.4.2.2 LIGHT DELIVERY SYSTEMS

4.4.2.3 HEALTHCARE FACILITY CHARGES

4.4.3 INDIRECT COSTS

4.4.3.1 PATIENT-RELATED EXPENSES

4.4.3.2 POST-TREATMENT MONITORING

4.4.4 COMPARATIVE COST-EFFECTIVENESS

4.4.5 REIMBURSEMENT AND INSURANCE IMPACT

4.4.6 REGIONAL COST VARIATIONS

4.4.7 FUTURE COST TRENDS AND REDUCTION STRATEGIES

4.4.7.1 TECHNOLOGICAL ADVANCEMENTS

4.4.7.2 HEALTHCARE EFFICIENCY INITIATIVES

4.4.8 CONCLUSION

4.5 TECHNOLOGICAL ADVANCEMENTS

4.5.1 INTRODUCTION

4.5.2 NEXT-GENERATION PHOTOSENSITIZERS

4.5.3 ADVANCEMENTS IN LIGHT DELIVERY SYSTEMS

4.5.4 NANOTECHNOLOGY-ENABLED DELIVERY

4.5.5 COMBINATION THERAPIES AND IMMUNOMODULATION

4.5.6 DIGITAL INTEGRATION AND TREATMENT PLANNING

4.5.7 RECENT TRENDS AND OUTLOOK

4.5.8 CONCLUSION

4.6 VALUE CHAIN ANALYSIS

4.6.1 INTRODUCTION

4.6.2 RESEARCH & DEVELOPMENT

4.6.2.1 DISCOVERY OF PHOTOSENSITIZERS

4.6.2.2 DEVELOPMENT OF LIGHT DELIVERY SYSTEMS

4.6.2.3 CLINICAL TRIALS AND REGULATORY APPROVALS

4.6.3 MANUFACTURING

4.6.3.1 PRODUCTION OF PHOTOSENSITIZERS

4.6.3.2 FABRICATION OF LIGHT DELIVERY DEVICES

4.6.4 DISTRIBUTION & LOGISTICS

4.6.4.1 SUPPLY CHAIN MANAGEMENT

4.6.4.2 INTERNATIONAL TRADE AND MARKET ACCESS

4.6.5 CLINICAL APPLICATION

4.6.5.1 INTEGRATION INTO TREATMENT PROTOCOLS

4.6.5.2 TRAINING AND EDUCATION

4.6.6 POST-TREATMENT MONITORING & SUPPORT

4.6.6.1 FOLLOW-UP CARE

4.6.6.2 PATIENT SUPPORT SERVICES

4.6.7 TECHNOLOGICAL ADVANCEMENTS INFLUENCING THE PDT VALUE CHAIN

4.6.7.1 NANOTECHNOLOGY IN PDT

4.6.7.2 ARTIFICIAL INTELLIGENCE AND IMAGING

4.6.7.3 PERSONALIZED MEDICINE

4.6.8 CONCLUSION

4.7 VENDOR SELECTION CRITERIA

4.7.1 INTRODUCTION

4.7.2 CORE SELECTION CRITERIA

4.7.2.1 REGULATORY COMPLIANCE

4.7.2.2 CLINICAL EVIDENCE AND RESEARCH SUPPORT

4.7.2.3 TECHNICAL PERFORMANCE AND DEVICE COMPATIBILITY

4.7.2.4 QUALITY MANAGEMENT AND MANUFACTURING STANDARDS

4.7.2.5 SERVICE, TRAINING, AND AFTER-SALES SUPPORT

4.7.2.6 SUPPLY CHAIN RELIABILITY

4.7.3 RECENT TRENDS IN VENDOR SELECTION

4.7.4 RISK FACTORS AND VULNERABILITIES

4.7.5 KEY PERFORMANCE INDICATORS

4.7.6 STRATEGIC RECOMMENDATIONS

4.7.7 CONCLUSION

4.8 PATENT ANALYSIS

4.8.1 PATENT QUALITY AND STRENGTH

4.8.2 PATENT FAMILIES

4.8.3 LICENSING AND COLLABORATIONS

4.8.4 REGIONAL PATENT LANDSCAPE

4.8.5 IP STRATEGY AND MANAGEMENT

4.9 SUPPLY CHAIN ANALYSIS

4.9.1 OVERVIEW

4.9.2 LOGISTIC COST SCENARIO

4.9.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS

4.9.4 CONCLUSION

4.1 INDUSTRY ECOSYSTEM ANALYSIS

4.10.1 INTRODUCTION

4.10.2 ECOSYSTEM ARCHITECTURE — KEY ACTORS AND ROLES

4.10.2.1 CORE TECHNOLOGY PROVIDERS

4.10.2.2 ENABLING INSTITUTIONS

4.10.3 VALUE CHAIN AND FUNCTIONAL FLOWS

4.10.3.1 RESEARCH AND DISCOVERY

4.10.3.2 CLINICAL DEVELOPMENT AND REGULATORY VALIDATION

4.10.3.3 MANUFACTURING AND QUALITY ASSURANCE

4.10.3.4 DISTRIBUTION, PROCUREMENT AND CLINICAL ADOPTION

4.10.4 MARKET ENABLERS AND INFRASTRUCTURE

4.10.4.1 SCIENTIFIC AND REGULATORY ENABLERS

4.10.4.2 REIMBURSEMENT AND HEALTH-ECONOMICS INFRASTRUCTURE

4.10.4.3 MANUFACTURING AND SUPPLY-CHAIN CAPACITY

4.10.5 INTERDEPENDENCIES AND STRATEGIC PARTNERSHIPS

4.10.5.1 ACADEMIA-INDUSTRY TECHNOLOGY TRANSFER

4.10.5.2 VERTICAL INTEGRATION AND CONTRACT MANUFACTURING

4.10.5.3 CLINICAL NETWORKS AND KOL ECOSYSTEMS

4.10.6 RISKS, CONSTRAINTS AND SYSTEMIC VULNERABILITIES

4.10.6.1 REGULATORY COMPLEXITY FOR COMBINED PRODUCTS

4.10.6.2 SUPPLY-CHAIN CONCENTRATION AND MATERIAL RISK

4.10.6.3 EVIDENCE AND REIMBURSEMENT UNCERTAINTY

4.10.6.4 CLINICAL OPERATIONAL BARRIERS

4.10.7 STRATEGIC IMPLICATIONS AND RECOMMENDATIONS

4.10.8 OUTLOOK — EVOLUTION OF THE ECOSYSTEM

4.10.9 CONCLUSION

4.11 INNOVATION TRACKER AND STRATEGIC ANALYSIS

4.11.1 INTRODUCTION

4.11.2 RECENT TECHNOLOGICAL INNOVATIONS

4.11.2.1 ADVANCED PHOTOSENSITIZERS

4.11.2.2 OXYGEN-SELF-SUFFICIENT PLATFORMS

4.11.2.3 ALTERNATIVE ACTIVATION MODALITIES

4.11.2.4 SMART NANOPLATFORMS

4.11.2.5 NOVEL CHEMICAL STRUCTURES

4.11.3 STRATEGIC INNOVATIONS IN DELIVERY SYSTEMS

4.11.3.1 LIGHT DELIVERY DEVICES

4.11.3.2 COMBINATION THERAPIES

4.11.3.3 IMAGING INTEGRATION

4.11.4 KEY CHALLENGES

4.11.5 STRATEGIC THEMES

4.11.6 STRATEGIC IMPLICATIONS FOR MARKET PLAYERS

4.11.7 RECOMMENDATIONS

4.11.8 OUTLOOK AND STRATEGIC RISKS

4.11.9 CONCLUSION

4.12 PRICING ANALYSIS

4.12.1 INTRODUCTION

4.12.2 COMPONENTS OF THE TOTAL TREATMENT PRICE

4.12.2.1 PHOTOSENSITIZING AGENT (DRUG) COSTS

4.12.2.2 DEVICE CAPITAL AND MAINTENANCE COST

4.12.2.3 CONSUMABLES AND PROCEDURAL OVERHEAD

4.12.2.4 INDIRECT AND DOWNSTREAM COSTS

4.12.3 PRICING MODELS AND APPROACHES

4.12.3.1 COST-PLUS AND MARKUP MODELS

4.12.3.2 VALUE-BASED AND OUTCOMES-LINKED PRICING

4.12.3.3 BUNDLED PAYMENTS AND PROCEDURAL TARIFFS

4.12.3.4 SUBSCRIPTION AND MANAGED-SERVICE MODELS FOR DEVICES

4.12.4 REIMBURSEMENT LANDSCAPE

4.12.4.1 UNITED STATES: MEDICARE AND COMMERCIAL PAYERS

4.12.4.2 EUROPE AND OTHER HIGH-INCOME MARKETS

4.12.4.3 EMERGING MARKETS AND OUT-OF-POCKET DYNAMICS

4.12.5 REGIONAL PRICE DIFFERENTIALS AND DRIVERS

4.12.5.1 MANUFACTURING FOOTPRINT AND SUPPLY-CHAIN EFFECTS

4.12.5.2 REGULATORY BURDEN AND MARKET ACCESS TIMELINES

4.12.5.3 CLINICAL PRACTICE PATTERNS AND REIMBURSEMENT POLICY

4.12.6 PRICE SENSITIVITY, ACCESS, AND EQUITY

4.12.6.1 PRICE ELASTICITY IN HOSPITAL PROCUREMENT

4.12.6.2 PATIENT ACCESS AND SOCIOECONOMIC BARRIERS

4.12.7 COMPETITIVE & STRATEGIC PRICING IMPLICATIONS

4.12.7.1 DIFFERENTIATION-BASED PREMIUM PRICING

4.12.7.2 PENETRATION PRICING AND VOLUME STRATEGIES

4.12.7.3 MANAGED ENTRY AGREEMENTS AND OUTCOMES GUARANTEES

4.12.8 RECOMMENDATIONS FOR STAKEHOLDERS

4.12.8.1 FOR MANUFACTURERS

4.12.8.2 FOR PROVIDERS AND HOSPITAL SYSTEMS

4.12.8.3 FOR PAYERS AND POLICYMAKERS

4.12.9 RISKS, UNCERTAINTIES, AND FUTURE PRICE PRESSURES

4.12.10 CONCLUSION

5 TARIFFS & IMPACT ON THE MARKET

5.1 INTRODUCTION

5.2 TARIFF LANDSCAPE RELEVANT TO PDT PRODUCTS

5.2.1 CATEGORIES OF TRADE EXPOSURE

5.2.2 RECENT AND EMERGING TARIFF MEASURES OF CONSEQUENCE

5.3 DIRECT COST IMPACTS

5.3.1 INCREASED LANDED COSTS AND MARGIN COMPRESSION

5.3.2 PRICE VOLATILITY AND PROCUREMENT BUDGETING

5.4 SUPPLY-CHAIN & MANUFACTURING IMPLICATIONS

5.4.1 SUPPLIER DIVERSIFICATION AND RESHORING INCENTIVES

5.4.2 SOURCING OF HIGH-VALUE NANOMATERIALS AND COMPONENTS

5.4.3 REGULATORY AND QUALIFICATION COSTS FOR NEW SUPPLIERS

5.5 CLINICAL ACCESS, PRICING & REIMBURSEMENT EFFECTS

5.5.1 ACCESS RISK FOR PATIENTS AND PROVIDERS

5.5.2 REIMBURSEMENT PRESSURE AND HEALTH-ECONOMIC ASSESSMENTS

5.6 R&D, INNOVATION & COMPETITIVE IMPLICATIONS

5.6.1 DISRUPTION OF RESEARCH SUPPLIES AND COLLABORATION FLOWS

5.6.2 STRATEGIC REPOSITIONING AND COMPETITIVE ADVANTAGE

5.7 POLICY, COMPLIANCE & REGULATORY CONSIDERATIONS

5.7.1 USE OF WTO AND PREFERENTIAL TRADE RULES

5.7.2 TARIFF MITIGATION TOOLS AND ADVOCACY

5.8 RECOMMENDATIONS FOR STAKEHOLDERS

5.9 CONCLUSION

6 REGULATION COVERAGE

6.1 PRODUCT CODES

6.1.1 CERTIFIED STANDARDS

6.1.2 SAFETY STANDARDS

6.1.3 MATERIAL HANDLING & STORAGE

6.1.4 TRANSPORT & PRECAUTIONS

6.1.5 HAZARD IDENTIFICATION

6.1.6 CONCLUSION

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF CANCER

7.1.2 GROWING PREFERENCE FOR MINIMALLY INVASIVE THERAPIES

7.1.3 TECHNOLOGICAL ADVANCEMENTS IN PHOTOSENSITIZERS AND DEVICES

7.1.4 EXPANDING RESEARCH AND CLINICAL DEVELOPMENT PIPELINE

7.2 RESTRAINTS

7.2.1 LIMITED DEPTH OF LIGHT PENETRATION

7.2.2 HIGH COST OF TREATMENT

7.3 OPPORTUNITIES

7.3.1 INTEGRATION WITH OTHER CANCER THERAPIES

7.3.2 DEVELOPMENT OF NOVEL PHOTOSENSITIZERS

7.3.3 M&A AND PARTNERSHIPS WITH ONCOLOGY DEVICE/LASER FIRMS AND PHARMA

7.4 CHALLENGES

7.4.1 TUMOR HYPOXIA AS A BIOLOGICAL BARRIER TO PHOTODYNAMIC THERAPY EFFICACY

7.4.2 COMPETITION FROM ALTERNATIVE TREATMENTS

8 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE

8.1 OVERVIEW

8.2 PHOTOSENSITIZER DRUGS

8.3 PHOTODYNAMIC THERAPY DEVICES

9 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION

9.1 OVERVIEW

9.2 SKIN & CUTANEOUS ONCOLOGY

9.3 HEAD & NECK

9.4 ESOPHAGAL

9.5 LUNG

9.6 BLADDER

9.7 CERVICAL

9.8 PROSTATE

10 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY

10.1 OVERVIEW

10.2 STANDALONE THERAPY

10.3 ADJUNCTIVE THERAPY

10.4 PALLIATION THERAPY

10.5 OTHERS

11 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE

11.1 OVERVIEW

11.2 EXTERNAL BEAM

11.3 INTRACAVITARY (ENDOSCOPIC) DELIVERY

11.4 INTERSTITIAL (INTERNAL) DELIVERY

11.5 OTHERS

12 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE

12.1 OVERVIEW

12.2 EARLY-STAGE CANCER

12.3 LATE-STAGE CANCER

13 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS

13.1 OVERVIEW

13.2 GERIATRIC

13.3 ADULTS

13.4 PEDIATRIC

14 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 DERMATOLOGY & SKIN-CANCER CLINICS

14.4 AMBULATORY SURGICAL CENTERS (ASCS)

14.5 ACADEMIC & RESEARCH INSTITUTES

14.6 OTHERS

15 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 THIRD PARTY DISTRIBUTORS

15.4 ONLINE

15.5 OTHERS

16 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION

16.1 EUROPE

16.1.1 GERMANY

16.1.2 U.K.

16.1.3 FRANCE

16.1.4 ITALY

16.1.5 SPAIN

16.1.6 RUSSIA

16.1.7 TURKEY

16.1.8 SWITZERLAND

16.1.9 BELGIUM

16.1.10 NETHERLANDS

16.1.11 SWEDEN

16.1.12 DENMARK

16.1.13 NORWAY

16.1.14 FINLAND

16.1.15 REST OF EUROPE

17 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: GLOBAL

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 NOVERTIS AG

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENT

19.2 GALDERMA S. A.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 PHOTOCURE

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 ADVANZ PHARMA CORP.

19.4.1 COMPANY SNAPSHOT

19.4.2 COMPANY SHARE ANALYSIS

19.4.3 PRODUCT PORTFOLIO

19.4.4 RECENT DEVELOPMENT

19.5 AMERISOURCE BERGEN CORPORATION

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENT

19.6 BIOFRONTERA AG

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENTS

19.7 BIOLITEC HOLDING GMBH & CO KG

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 CARDINAL HEALTH

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENT

19.9 HEMERION THERAPEUTICS

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENTS

19.1 IMPACT BIOTECH

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENTS

19.11 INOVA

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENT

19.12 LUMIBIRD

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENT

19.13 LUZITIN

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENT

19.14 MCKESSON

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENTS

19.15 MODULIGHT CORPORATION

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENT

19.16 ONCOLUX INC (FORMERLY LUMEDA INC.)

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 SUN PHARMACEUTICAL INDUSTRIES LTD

19.17.1 COMPANY SNAPSHOT

19.17.2 REVENUE ANALYSIS

19.17.3 PRODUCT PORTFOLIO

19.17.4 RECENT DEVELOPMENT

19.18 THERALASE TECHNOLOGIES INC.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

Lista de Tabela

TABLE 1 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 2 EUROPE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2019-2028 (USD THOUSAND)

TABLE 3 EUROPE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 4 EUROPE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 5 EUROPE PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 6 EUROPE PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 7 EUROPE LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 EUROPE ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 9 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 10 EUROPE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 11 EUROPE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 12 EUROPE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 13 EUROPE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 14 EUROPE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 15 EUROPE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 16 EUROPE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 17 EUROPE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 18 EUROPE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 19 EUROPE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 20 EUROPE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 EUROPE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 22 EUROPE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 23 EUROPE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 24 EUROPE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 25 EUROPE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 26 EUROPE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 27 EUROPE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 28 EUROPE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 29 EUROPE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 EUROPE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 31 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 32 EUROPE STANDALONE THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 33 EUROPE ADJUNCTIVE THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 34 EUROPE PALLIATION THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 35 EUROPE OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 36 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 37 EUROPE EXTERNAL BEAM IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 38 EUROPE INTRACAVITARY (ENDOSCOPIC) DELIVERY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 39 EUROPE INTERSTITIAL (INTERNAL) DELIVERY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 40 EUROPE OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 41 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 42 EUROPE EARLY-STAGE CANCER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 43 EUROPE LATE-STAGE CANCER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 44 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 45 EUROPE GERIATRIC IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 46 EUROPE ADULTS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 47 EUROPE PEDIATRIC IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 48 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 49 EUROPE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 50 EUROPE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51 EUROPE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 52 EUROPE DERMATOLOGY & SKIN-CANCER CLINICS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 53 EUROPE AMBULATORY SURGICAL CENTERS (ASCS) IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 54 EUROPE ACADEMIC & RESEARCH INSTITUTES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 55 EUROPE OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 56 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 57 EUROPE DIRECT TENDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 58 EUROPE THIRD PARTY DISTRIBUTORS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 59 EUROPE ONLINE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 60 EUROPE OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 61 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 62 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 63 EUROPE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 64 EUROPE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 65 EUROPE PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 66 EUROPE LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 EUROPE ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 68 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 69 EUROPE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 70 EUROPE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 71 EUROPE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 72 EUROPE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 73 EUROPE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 74 EUROPE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 75 EUROPE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 76 EUROPE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 77 EUROPE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 78 EUROPE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 79 EUROPE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 80 EUROPE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 81 EUROPE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 EUROPE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 83 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 84 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 85 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 86 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 87 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 88 EUROPE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 89 EUROPE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 90 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 91 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 92 GERMANY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 93 GERMANY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 94 GERMANY PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 95 GERMANY LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 96 GERMANY ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 97 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 98 GERMANY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 99 GERMANY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 100 GERMANY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 101 GERMANY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 102 GERMANY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 103 GERMANY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 104 GERMANY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 105 GERMANY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 106 GERMANY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 107 GERMANY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 108 GERMANY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 GERMANY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 110 GERMANY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 GERMANY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 112 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 113 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 114 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 115 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 116 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 117 GERMANY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 118 GERMANY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 119 GERMANY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 120 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 121 U.K. PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 122 U.K. PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 123 U.K. PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 124 U.K. LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 U.K. ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 127 U.K. SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 128 U.K. SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 129 U.K. HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 130 U.K. HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 131 U.K. ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 U.K. ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 133 U.K. LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 134 U.K. LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 135 U.K. BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 136 U.K. BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 137 U.K. CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 138 U.K. CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 139 U.K. PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 U.K. PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 141 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 142 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 143 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 144 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 145 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 146 U.K. HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 147 U.K. HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 148 U.K. CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 149 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 FRANCE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 151 FRANCE PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 152 FRANCE PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 153 FRANCE LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 FRANCE ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 156 FRANCE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 157 FRANCE SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 158 FRANCE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 FRANCE HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 160 FRANCE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 FRANCE ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 162 FRANCE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 163 FRANCE LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 164 FRANCE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 FRANCE BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 166 FRANCE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 FRANCE CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 168 FRANCE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 FRANCE PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 170 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 171 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 172 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 173 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 174 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 175 FRANCE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 176 FRANCE HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 177 FRANCE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 178 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 ITALY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 180 ITALY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 181 ITALY PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 ITALY LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 183 ITALY ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 184 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 185 ITALY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 186 ITALY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 187 ITALY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 188 ITALY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 189 ITALY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 ITALY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 191 ITALY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 192 ITALY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 193 ITALY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 194 ITALY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 195 ITALY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 ITALY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 197 ITALY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 198 ITALY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 199 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 200 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 201 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 202 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 203 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 204 ITALY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 ITALY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 206 ITALY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 207 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 SPAIN PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 209 SPAIN PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 210 SPAIN PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 SPAIN LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 SPAIN ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 213 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 214 SPAIN SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 SPAIN SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 216 SPAIN HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 SPAIN HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 218 SPAIN ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 SPAIN ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 220 SPAIN LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 221 SPAIN LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 222 SPAIN BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 SPAIN BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 224 SPAIN CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 SPAIN CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 226 SPAIN PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 SPAIN PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 228 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 229 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 230 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 231 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 232 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 233 SPAIN HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 234 SPAIN HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 235 SPAIN CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 236 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 RUSSIA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 238 RUSSIA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 239 RUSSIA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 240 RUSSIA LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 241 RUSSIA ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 242 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 243 RUSSIA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 244 RUSSIA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 245 RUSSIA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 RUSSIA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 247 RUSSIA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 248 RUSSIA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 249 RUSSIA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 RUSSIA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 251 RUSSIA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 RUSSIA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 253 RUSSIA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 RUSSIA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 255 RUSSIA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 RUSSIA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 257 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 258 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 259 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 260 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 261 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 262 RUSSIA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 263 RUSSIA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 264 RUSSIA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 265 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 TURKEY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 267 TURKEY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 268 TURKEY PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 TURKEY LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 TURKEY ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 271 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 272 TURKEY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 TURKEY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 274 TURKEY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 TURKEY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 276 TURKEY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 TURKEY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 278 TURKEY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 TURKEY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 280 TURKEY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 281 TURKEY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 282 TURKEY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 283 TURKEY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 284 TURKEY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 TURKEY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 286 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 287 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 288 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 289 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 290 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 291 TURKEY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 292 TURKEY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 293 TURKEY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 294 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 295 SWITZERLAND PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 296 SWITZERLAND PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 297 SWITZERLAND PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 298 SWITZERLAND LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 299 SWITZERLAND ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 301 SWITZERLAND SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 SWITZERLAND SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 303 SWITZERLAND HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 SWITZERLAND HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 305 SWITZERLAND ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 SWITZERLAND ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 307 SWITZERLAND LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 308 SWITZERLAND LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 309 SWITZERLAND BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 310 SWITZERLAND BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 311 SWITZERLAND CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 312 SWITZERLAND CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 313 SWITZERLAND PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 314 SWITZERLAND PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 315 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 316 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 317 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 318 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 319 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 320 SWITZERLAND HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 321 SWITZERLAND HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 322 SWITZERLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 323 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 324 BELGIUM PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 325 BELGIUM PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 326 BELGIUM PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 BELGIUM LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 328 BELGIUM ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 330 BELGIUM SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 331 BELGIUM SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 332 BELGIUM HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 333 BELGIUM HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 334 BELGIUM ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 BELGIUM ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 336 BELGIUM LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 BELGIUM LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 338 BELGIUM BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 339 BELGIUM BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 340 BELGIUM CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 341 BELGIUM CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 342 BELGIUM PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 BELGIUM PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 344 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 345 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 346 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 347 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 348 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 349 BELGIUM HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 BELGIUM HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 351 BELGIUM CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 352 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 353 NETHERLANDS PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 354 NETHERLANDS PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 355 NETHERLANDS PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 NETHERLANDS LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 NETHERLANDS ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 359 NETHERLANDS SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 NETHERLANDS SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 361 NETHERLANDS HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 NETHERLANDS HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 363 NETHERLANDS ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 364 NETHERLANDS ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 365 NETHERLANDS LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 366 NETHERLANDS LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 367 NETHERLANDS BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 368 NETHERLANDS BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 369 NETHERLANDS CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 NETHERLANDS CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 371 NETHERLANDS PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 NETHERLANDS PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 373 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 374 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 375 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 376 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 377 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 378 NETHERLANDS HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 NETHERLANDS HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 380 NETHERLANDS CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 381 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 SWEDEN PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 383 SWEDEN PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 384 SWEDEN PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 SWEDEN LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 386 SWEDEN ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 388 SWEDEN SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 389 SWEDEN SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 390 SWEDEN HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 391 SWEDEN HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 392 SWEDEN ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 393 SWEDEN ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 394 SWEDEN LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 395 SWEDEN LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 396 SWEDEN BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 397 SWEDEN BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 398 SWEDEN CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 399 SWEDEN CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 400 SWEDEN PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 SWEDEN PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 402 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 403 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 404 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 405 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 406 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 407 SWEDEN HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 SWEDEN HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 409 SWEDEN CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 410 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 411 DENMARK PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 412 DENMARK PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 413 DENMARK PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 414 DENMARK LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 DENMARK ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 417 DENMARK SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 418 DENMARK SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 419 DENMARK HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 420 DENMARK HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 421 DENMARK ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 DENMARK ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 423 DENMARK LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 424 DENMARK LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 425 DENMARK BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 426 DENMARK BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 427 DENMARK CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 428 DENMARK CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 429 DENMARK PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 430 DENMARK PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 431 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 432 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 433 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 434 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 435 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 436 DENMARK HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 437 DENMARK HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 438 DENMARK CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 439 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 440 NORWAY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 441 NORWAY PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 442 NORWAY PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 443 NORWAY LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 444 NORWAY ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 445 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 446 NORWAY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 447 NORWAY SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 448 NORWAY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 449 NORWAY HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 450 NORWAY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 451 NORWAY ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 452 NORWAY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 453 NORWAY LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 454 NORWAY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 455 NORWAY BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 456 NORWAY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 457 NORWAY CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 458 NORWAY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 459 NORWAY PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 460 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 461 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 462 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 463 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 464 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 465 NORWAY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 466 NORWAY HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 467 NORWAY CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 468 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 469 FINLAND PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 470 FINLAND PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)

TABLE 471 FINLAND PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 472 FINLAND LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 473 FINLAND ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 474 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)

TABLE 475 FINLAND SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 476 FINLAND SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 477 FINLAND HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 478 FINLAND HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 479 FINLAND ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 480 FINLAND ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 481 FINLAND LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 482 FINLAND LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 483 FINLAND BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 484 FINLAND BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 485 FINLAND CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 486 FINLAND CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 487 FINLAND PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 488 FINLAND PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 489 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)

TABLE 490 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)

TABLE 491 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)

TABLE 492 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 493 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 494 FINLAND HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 495 FINLAND HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)

TABLE 496 FINLAND CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 497 REST OF EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

Lista de Figura

FIGURE 1 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: SEGMENTATION

FIGURE 2 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: DROC ANALYSIS

FIGURE 4 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: EUROPE VS REGIONAL ANALYSIS

FIGURE 5 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: SEGMENTATION

FIGURE 10 EXECUTIVE SUMMARY

FIGURE 11 STRATEGIC DECISIONS

FIGURE 12 TWO SEGMENTS COMPRISE THE EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE (2024)

FIGURE 13 INCREASING PREVALENCE OF CANCER ACROSS GLOBE EXPECTED TO DRIVE THE EUROPE CANCER PHOTODYNAMIC THERAPY MARKET IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 14 PHOTOSENSITIZER DRUGS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CANCER PHOTODYNAMIC THERAPY MARKET IN 2025 & 2032

FIGURE 15 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET-MARKET OVERVIEW

FIGURE 16 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2024

FIGURE 17 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2024

FIGURE 18 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032

FIGURE 19 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032

FIGURE 20 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2024

FIGURE 21 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2024

FIGURE 22 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032

FIGURE 23 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032

FIGURE 24 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2024

FIGURE 25 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2024

FIGURE 26 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032

FIGURE 27 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032

FIGURE 28 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2024

FIGURE 29 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2024

FIGURE 30 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032

FIGURE 31 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032

FIGURE 32 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2024

FIGURE 33 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2024

FIGURE 34 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032

FIGURE 35 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032

FIGURE 36 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2024

FIGURE 37 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032

FIGURE 38 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032

FIGURE 39 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032

FIGURE 40 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2024

FIGURE 41 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2024

FIGURE 42 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032

FIGURE 43 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032

FIGURE 44 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024

FIGURE 45 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024

FIGURE 46 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032

FIGURE 47 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032

FIGURE 48 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: SNAPSHOT (2024)

FIGURE 49 EUROPE CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY SHARE 2024 (%)

View Detailed Information

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

Quais são os principais segmentos abordados no relatório Relatório sobre o tamanho, participação e tendências do mercado?

O mercado é segmentado com base em Segmentação do Mercado Europeu de Terapia Fotodinâmica para o Câncer, por Tipo de Produto (Medicamentos Fotossensibilizadores, Dispositivos de Terapia Fotodinâmica), por Indicação de Câncer (Oncologia Cutânea, Cabeça e Pescoço, Esôfago, Pulmão, Bexiga, Colo do Útero, Próstata), por Modalidade de Terapia (Terapia Isolada, Terapia Adjuvante, Terapia Paliativa, Outras), por Técnica de Procedimento (Feixe Externo, Administração Intracavitária (Endoscópica), Administração Intersticial (Interna), Outras), por Estágio da Doença (Câncer em Estágio Inicial, Câncer em Estágio Avançado), por Perfil Demográfico do Paciente (Idosos, Adultos, Crianças), por Usuário Final (Hospitais, Clínicas de Dermatologia e Câncer de Pele, Centros Cirúrgicos Ambulatoriais (CCAs), Institutos Acadêmicos e de Pesquisa, Outros), por Canal de Distribuição (Licitações Diretas, Distribuidores Terceirizados, Online, Outros) - Tendências e Previsões do Setor até 2032 .

Qual é o tamanho atual do mercado de Relatório sobre o tamanho, participação e tendências do mercado?

O tamanho do Relatório sobre o tamanho, participação e tendências do mercado foi avaliado em USD 872.14 USD Million no ano de 2024.

Qual é a taxa de crescimento esperada para Relatório sobre o tamanho, participação e tendências do mercado?

O Relatório sobre o tamanho, participação e tendências do mercado está projetado para crescer a um CAGR de 5.8% durante o período de previsão de 2025 a 2032.

Quem são os principais players do Relatório sobre o tamanho, participação e tendências do mercado?

Os principais players do mercado incluem Novartis Pharma AG ,Galderma SA ,Bausch Health Companies Inc. ,Photocure ASA ,ADVANZ PHARMA Corp. ,Sun Pharmaceutical Industries Ltd..

Relatório sobre o tamanho, participação e tendências do mercado europeu de terapia fotodinâmica para o câncer – Visão geral do setor e previsão até 2032

Contorne os desafios das tarifas com uma consultoria ágil da cadeia de abastecimento

Europe Cancer Photodynamic Therapy Market

CAGR : 5.80 %

Tamanho do mercado europeu de terapia fotodinâmica para o câncer

Análise do mercado europeu de terapia fotodinâmica para o câncer

Escopo do relatório e segmentação do mercado europeu de terapia fotodinâmica para o câncer.

Análises Essenciais do Mercado da Seda

Tendências do mercado europeu de terapia fotodinâmica para o câncer

Dinâmica do mercado europeu de terapia fotodinâmica para o câncer

Escopo do mercado europeu de terapia fotodinâmica para o câncer

Análise Regional do Mercado Europeu de Terapia Fotodinâmica para o Câncer

Últimos desenvolvimentos no mercado europeu de terapia fotodinâmica para o câncer

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Relatórios

Informações de mercado

Apoiar

Soluções

Relatório sobre o tamanho, participação e tendências do mercado europeu de terapia fotodinâmica para o câncer – Visão geral do setor e previsão até 2032

Contorne os desafios das tarifas com uma consultoria ágil da cadeia de abastecimento

Europe Cancer Photodynamic Therapy Market

CAGR : 5.80 %

Tamanho do mercado europeu de terapia fotodinâmica para o câncer

Análise do mercado europeu de terapia fotodinâmica para o câncer

Escopo do relatório e segmentação do mercado europeu de terapia fotodinâmica para o câncer.

Análises Essenciais do Mercado da Seda

Tendências do mercado europeu de terapia fotodinâmica para o câncer

Dinâmica do mercado europeu de terapia fotodinâmica para o câncer

Escopo do mercado europeu de terapia fotodinâmica para o câncer

Análise Regional do Mercado Europeu de Terapia Fotodinâmica para o Câncer

Últimos desenvolvimentos no mercado europeu de terapia fotodinâmica para o câncer

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Navegue pelas páginas relacionadas